Center for Clinical Studies
Center for Clinical Studies
Webster, Texas, United States12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Moderate to Severe Glabellar Lines | Active, not recruiting | Phase 3 | 2026-10-01 | NCT07435428 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06220604 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06095102 | |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-22 | NCT07116967 | |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, nutritional disorder, obesity disorder, overnutrition, psoriasis, skin disorder | Recruiting | Phase 4 | 2026-09-04 | NCT06857942 | |
| A Study of Barzolvolimab in Patients With Prurigo Nodularis | prurigo nodularis | Active, not recruiting | Phase 2 | 2026-08-04 | NCT06366750 | |
| Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-06-15 | NCT06397911 | |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | prurigo nodularis | Active, not recruiting | Phase 3 | 2026-05-28 | NCT06516952 | |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | Bacterial Infections and Mycoses, Chronic Disease, Chronic Spontaneous Urticaria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Hypersensitivity, Immediate, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Suppuration, alopecia, alopecia areata, atopic eczema, bacterial infectious disease, chronic urticaria, dermatitis, disorder of pilosebaceous unit, hereditary disease, hereditary skin disorder, hidradenitis, hidradenitis suppurativa, hypopigmentation of the skin, hypotrichosis, immune system disorder, psoriasis, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, skin pigmentation disorder, skin vascular disease, sweat gland disorder, urticaria, vitiligo | Active, not recruiting | Not stated | 2026-03-20 | NCT03661866 |